Scinai Raises $1.69M from Warrants, CEO Sends Shareholder Letter

Ticker: SCNI · Form: 6-K · Filed: 2024-01-04T00:00:00.000Z

Sentiment: neutral

Topics: capital-raise, warrant-exercise, shareholder-letter, biotechnology

TL;DR

**Scinai just raised $1.69M from warrants, boosting cash for operations.**

AI Summary

Scinai Immunotherapeutics Ltd. filed a 6-K on January 4, 2024, announcing two key events: a letter to shareholders from CEO Amir Reichman and the closing of warrant exercises that generated $1.69 million in gross proceeds. This capital infusion provides Scinai with additional funds, which is crucial for a biotech company to advance its pipeline and operations. For investors, this means the company has strengthened its cash position, potentially reducing the need for immediate dilutive financing and supporting its ongoing research and development efforts.

Why It Matters

The $1.69 million raised from warrant exercises provides Scinai with fresh capital, which is vital for funding its operations and pipeline development, potentially reducing immediate reliance on further stock dilution. The CEO's letter offers transparency and insight into the company's strategic direction.

Risk Assessment

Risk Level: medium — While the capital raise is positive, biotech companies like Scinai inherently carry medium to high risk due to the long development cycles and uncertainties of drug approval.

Analyst Insight

An investor should view the $1.69 million capital raise as a positive, non-dilutive event that strengthens Scinai's balance sheet, but also consider the broader context of the company's long-term financial needs and pipeline progress. Reviewing the full shareholder letter (Exhibit 99.1) would provide further strategic insights.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What was the primary purpose of Scinai Immunotherapeutics Ltd.'s 6-K filing on January 4, 2024?

The primary purpose was to furnish two press releases: one containing a letter to shareholders from CEO Amir Reichman, and another announcing the closing of warrant exercises that generated $1.69 million in gross proceeds.

Who is Amir Reichman and what was his involvement in this filing?

Amir Reichman is the Chief Executive Officer of Scinai Immunotherapeutics Ltd., and a letter from him to shareholders was included as part of the press release furnished with this 6-K filing.

How much capital did Scinai Immunotherapeutics Ltd. raise from the exercise of outstanding warrants?

Scinai Immunotherapeutics Ltd. announced the closing of the exercise of outstanding warrants for $1.69 million in gross proceeds.

Which specific exhibits were furnished with this 6-K filing?

Exhibit 99.1, which is a press release with a letter to shareholders from Mr. Amir Reichman, and Exhibit 99.2, which is a press release announcing the closing of warrant exercises for $1.69 million in gross proceeds, were furnished.

Into which registration statements were the exhibits from this 6-K incorporated by reference?

Exhibit 99.1 (with certain exclusions) and Exhibit 99.2 were incorporated by reference into the registrant's Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344) and Form F-3 (File No. 333-274078).

From the Filing

0001213900-24-001202.txt : 20240104 0001213900-24-001202.hdr.sgml : 20240104 20240104163715 ACCESSION NUMBER: 0001213900-24-001202 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240104 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 24512636 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea191163-6k_scinaiimmun.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of January 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note On January 4, 2024, Scinai Immunotherapeutics Ltd. (“Scinai”) issued a press release with a letter to shareholders from Mr. Amir Reichman, the Chief Executive Officer . A copy of the press release is furnished herewith as Exhibit 99.1. Exhibit 99.1 (other than (i) the paragraph immediately preceding “Pipeline Development”, (ii) the paragraph starting with “Professor Amos Gilhar of the Technion…, “, (iii) the paragraph entitled “New Name and Brand” and (iv) links to Scinai’s website and videos) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. On January 4, 2024, Scinai issued a press release announcing closing of exercise of outstanding warrants for $1.69 million in gross proceeds . A copy of the press release is furnished herewith as Exhibit 99.2. Exhibit 99.2 is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 Exhibit Index Exhibit No. Description 99.1 Scinai Immunotherapeutics CEO Issues Letter to Shareholders. 99.2 Press Release dated January 4, 2024, “Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds” 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: January 4, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3 EX-99.1 2 ea191163ex99-1_scinaiimmun.htm SCINAI IMMUNOTHERAPEUTICS CEO ISSUES LETTER TO SHAREHOLDERS Exhibit 99.1 Scinai Immunotherapeutics CEO Issues Letter to Shareholders JERUSALEM, ISRAEL &nd

View on Read The Filing